DMARDs are a medication that suppresses the immune system. People may take them to slow disease progression in autoimmune or inflammatory conditions, such as different types of arthritis. Inflammation ...
Patients with Medicare Part D insurance plans experience uneven and “restrictive” coverage of certain drugs and drug classes ...
New disease-modifying anti-rheumatic drugs (DMARDs) for rheumatoid arthritis are usually expensive and insurers, including Medicare, will often limit access. This study examined Medicare Advantage and ...
The use of newer biologic or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) for treating juvenile idiopathic arthritis (JIA) rose sharply from 2001 to 2022, while the use of ...
Early diagnosis leads to earlier treatment. With earlier treatment of rheumatoid arthritis (RA), there is a better chance for less radiographic damage, less disability and thus lower overall costs of ...
In recent years, the treatment of rheumatic inflammatory diseases has been revolutionized. With the advent of biologic and targeted synthetic disease-modifying antirheumatic drugs (DMARDs), minimal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results